清开灵注射液治疗急性上呼吸道感染的临床研究

目的 探讨清开灵注射液（简称清开灵）对急性发热的疗效。方法 每日采用清开灵１２０，１６０，２００ｍｌ３个剂量，并以洁霉素注射液（简称洁霉素）１．８ｇ对照，观察急性上呼吸道感染患者４００例的疗效。结果 清开灵愈显率８４．１４％，洁霉素愈显率７５．８３％前者疗效优于后者（Ｐ〈０．０１）。清开灵（一次性常规剂量）降低体温平均起效时间（１２．６ｈ）较洁霉素（１７．６ｈ）短，清开灵对病程１天以内的患者，疗效

Clinical Study on Acute Upper Respiratory Tract Infection Treated with Qingkailing Injection

Objective: To explore the effect of Qingkailing injection (QKLI) in treating acute fever, Methods: Four hundred cases of acute upper respiratory tract infection were divided into three groups treated with QKLI 120 ml/d, 160ml/d and 200 ml/d respectively, and compared with a control group treated with lincomycin 1.8g/d. Results: The markedly effective rate of QKLI was 84.14% which was better than that of lincomycin (75.83%) . The mean initial time of QKLI (12.6h) was shorter than that of lincomycin (17.6h). Effect of QKLI on patients with disease course within one day was better than that within 3 days. No significant difference revealed between effects in groups treated with different dosage of QKLI. The effect of QKLI in lowering white blood cell count was similar to that of lincomycin. For patients with positive throat swab culture of pathogenic bacteria, QKLI displayed good antibacterial action in vivo. Conclusion: QKLI is a highly effective with rapid action drug for treatment of acute respiratory infection.